References
- McPhee SJ, Papadakis MA, Tierney LM. Current medical diagnosis and treatment. New York: McGraw-Hill Medical; 2010.
- Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.
- Zhu X, Radovic-Moreno AF, Wu J, et al. Nanomedicine in the management of microbial infection - overview and perspectives. Nano Today. 2014;9:478–498.
- Garg T. Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne. Artif Cells Nanomed Biotechnol. 2016;44:98–105.
- Obonyo M, Zhang L, Thamphiwatana S, et al. Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori. Mol Pharmaceutics. 2012;9:2677–2685.
- Farrington M, Brenwald N, Haines D, et al. Resistance to desiccation and skin fatty acids in outbreak strains of methicillin-resistant Staphylococcus aureus. J Med Microbiol. 1992;32:56–60.
- Tille P. Bailey & Scott’s diagnostic microbiology. London: Elsevier Health Sciences; 2013.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-Fifth Informational Supplement. Wayne (PA): CLSI; 2015. Document M100-S25.
- Bessa LJ, Fazii P, Di Giulio M, et al. Bacterial isolates from infected wounds and their antibiotic susceptibility pattern: some remarks about wound infection. Int Wound J. 2015;12:47–52.
- Dua JS, Rana AC, Bhandari AK. Liposome: methods of preparation and applications. Int J Pharm Stud Res. 2012;3:14–20.
- Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010;10:441–451.
- Abed N, Couvreur P. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int J Antimicrob Agents. 2014;43:485–496.
- Collins D, Norley ST, Rouse B, et al. Liposomes as carriers for antitumor and antiviral drugs: pH- sensitive immunoliposomes and sustained release immunoliposomes. In: Ciregoriadis G, editor. Liposomes as drug carriers. New York: Wiley; 1988. p. 761–770.
- Daraee H, Etamadi A, Kouhi M, et al. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol. 2016;44:381–391.
- Huang CM, Chen CH, Pornpattananangkul D, et al. Eradication of drug resistant Staphylococcus aureus by liposomal oleic acids. Biomaterials. 2011;32:214–221.
- Srisuk P, Thongnopnua P, Raktanonchai U, et al. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment. Int J Pharm. 2012;427:426–434.
- Broccard AF, Shapiro RS, Schmitz LL, et al. Influence of prone position on the extent and distribution of lung injury in a high tidal volume oleic acid model of acute respiratory distress syndrome. Crit Care Med. 1997;25:16–27.
- Kenny JG, Ward D, Josefsson E, et al. The Staphylococcus aureus response to unsaturated long chain free fatty acids: survival mechanisms and virulence implications. PLoS One. 2009;4:e4344.